Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide vs Iberdomide Plus Isatuximab Maintenance Therapy Post-ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158Phase 3Active, not recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of isatuximab in multiple myeloma (MM). Started Apr 2024; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06216158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216158.